Eledon Pharmaceuticals (Nasdaq:ELDN) - Aktienkurs, Nachrichten und Analyse

ELDN Aktienübersicht

Eledon Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase. Mehr Details

ELDN grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 33% pro Jahr sinken.

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Volatiler Aktienkurs in den letzten 3 Monaten

+ 1 mehr Risiko

Eledon Pharmaceuticals, Inc. Wettbewerber

Mersana Therapeutics

NasdaqGS:MRSN

US$247.1m

Benitec Biopharma

NasdaqCM:BNTC

US$235.6m

aTyr Pharma

NasdaqCM:ATYR

US$261.9m

Fate Therapeutics

NasdaqGM:FATE

US$275.6m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Eledon Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	US$4.25
52-Wochen-Hoch	US$5.54
52-Wochen-Tief	US$1.11
Beta	0.77
11 Monat Veränderung	25.37%
3 Monate Veränderung	49.12%
1 Jahr Veränderung	254.17%
33 Jahre Veränderung	-13.09%
5 Jahre Veränderung	-61.29%
Veränderung seit IPO	-96.30%

Aktuelle Nachrichten und Updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Aktionärsrenditen

	ELDN	US Biotechs	US Markt
7D	9.5%	4.0%	2.0%
1Y	254.2%	18.0%	32.4%

Rendite im Vergleich zur Industrie: ELDN übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 18 erzielte.

Rendite vs. Markt: ELDN übertraf den Markt US, der im vergangenen Jahr eine Rendite von 32.4 erzielte.

Preisvolatilität

Is ELDN's price volatile compared to industry and market?
ELDN volatility
ELDN Average Weekly Movement	10.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: ELDNDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: ELDNDie wöchentliche Volatilität (11%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	20	DA Gros	eledon.com

Eledon Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase. Das Unternehmen nutzt sein immunologisches Fachwissen bei der Ausrichtung auf den CD40-Liganden (CD40L, auch CD154 genannt), um Therapien zum Schutz transplantierter Organe und zur Verhinderung von Abstoßungsreaktionen sowie zur Behandlung von amyotropher Lateralsklerose (ALS) zu entwickeln. Der führende Wirkstoff des Unternehmens in der Entwicklung ist Tegoprubart, ein IgG1- und Anti-CD40L-Antikörper mit hoher Affinität zum CD40-Liganden, einem biologischen Ziel mit therapeutischem Potenzial.

Eledon Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Eledon Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
ELDN grundlegende Statistiken
Marktanteil	US$239.55m
Gewinn(TTM)	-US$24.55m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-10.3x

Kurs-Gewinn-Verhältnis

Ist ELDN zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ELDN Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$24.55m
Umsatz	-US$24.55m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.41
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich ELDN auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ELDN Aktienübersicht

Risikoanalyse

Eledon Pharmaceuticals, Inc. Wettbewerber

NasdaqGS:MRSN

US$247.1m

NasdaqCM:BNTC

US$235.6m

NasdaqCM:ATYR

US$261.9m

NasdaqGM:FATE

US$275.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Price target decreased by 20% to US$12.50

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Recent updates

Price target decreased by 20% to US$12.50

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Price target decreased by 10% to US$14.00

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

New minor risk - Share price stability

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Price target decreased by 10% to US$16.50

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Price target decreased to US$19.40

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$28.80

Price target decreased to US$29.75

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought US$89k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon gives update on development strategy for AT-1501 in renal transplantation

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: US$12.66

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

New 90-day low: US$14.76

Price target raised to US$35.00

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics EPS misses by $3.76

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Erträge & Einnahmen